Open Accessibility Menu
Hide

Monoclonal Antibody Therapy

Monoclonal antibody therapy is not available at this time. St. Claire HealthCare's supply of the medication has been depleted.

If you test positive for COVID-19 or know you were exposed to COVID-19 and are at high risk for complications, you may benefit from monoclonal antibody therapy.

Monoclonal antibody therapy is used for the treatment of patients with mild to moderate COVID-19 who are at increased risk for progressing to severe disease and/or requiring hospitalization. It is also used to prevent COVID-19 in patients who have been exposed to the virus and are at increased risk of progressing to severe disease and/or requiring hospitalization.

Monoclonal antibody therapy is not available for patients who require oxygen to treat their COVID-19 symptoms.

If any of the criteria below apply to you, you may be eligible for monoclonal antibody therapy.

  • Older age (Ex: age ≥65 years of age)
  • Obesity or being overweight
  • Pregnancy
  • Chronic kidney disease
  • Diabetes
  • Immunosuppressive disease or immunosuppressive treatment (like daily prednisone)
  • Heart disease (including congenital heart disease)
  • Hypertension
  • Lung diseases (Ex: chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis, or pulmonary hypertension)
  • Sickle cell disease
  • Neurodevelopmental problems (Ex: cerebral palsy) or other conditions that confer medical complexity (Ex: genetic or metabolic syndromes, or severe congenital anomalies)
  • Having a medical-related technological dependence (Ex: tracheostomy, gastrostomy, or positive pressure ventilation not related to COVID-19)

The FDA has authorized monoclonal antibody therapy for emergency use. It is given either as an infusion or as a series of injections under the skin. Treatment usually takes about two hours from start to finish.

Monoclonal antibody therapy is not available at this time. St. Claire HealthCare's supply of the medication has been depleted.

There has been a very rapid change in COVID in Kentucky over the last two weeks and the Omicron variant is now dominant. Two of the three monoclonal antibodies FDA-authorized for COVID-19 in the United States, REGEN-COV and bam/ete, are ineffective against the Omicron variant. As such, new shipments of REGEN-COV and bam/ete to Kentucky have ended as of January 3, 2022. The third FDA-authorized monoclonal antibody, sotrovimab, is available in only very limited quantities. Unless sotrovimab supplies increase and/or new monoclonal antibodies effective against the Omicron variant are released, supplies will be extremely limited.